Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

MYSTERIOUS: Kala pharmaceuticals s return on capital employed insights - You Need To See This

Benzinga Pro data, Kala Pharmaceuticals (NASDAQ:KALA) reported Q4 sales of $1.86 million. Earnings fell to a loss of $47.57 million, resulting in a 69.12% decrease from last quarter. Kala Pharmaceuticals collected $3.07 million in revenue during Q3, but reported earnings showed a $28.13 million loss.

What Is Return On Capital Employed?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.